Press Releases

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the Module 1 review of the company's FDA premarket approval application (PMA) submission is progressing as expected.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, brings together top anti-reflux surgeons in Spain to create a community of excellence to share RefluxStop™ data, insights, and the best practices, driving advancements in the surgical treatment field of gastroesophageal reflux disease (GERD).

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, reports the study, “Analysis of Cost-Effectiveness in Switzerland for a New Implantable Device to Treat Chronic Gastroesophageal Reflux Disease,” was published recently by the Journal of Medical Economics (https://pubmed.ncbi.nlm.nih.gov/38820006/#:~:text=Gastroesophageal%20reflux%20disease%20(GERD)%20is,MSA%5D)%20in%20selected%20cases)1.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that another NHS Trust hospital, the University Hospital Southampton, a leading public teaching hospital in the south of England, is now performing the RefluxStop™ procedure.

Today, May 22, 2024, the annual general meeting (the “AGM”) of Implantica AG (publ) was held in Ruggel, Liechtenstein. The general meeting resolved to adopt all of the board of directors’ resolution proposals. A summary of the resolutions adopted at the general meeting is set out below.

RefluxStop™ on path to become standard of care for acid reflux treatment

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, welcomes a new hospital performing the RefluxStop™ procedure in Italy, Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone.

Implantica AG (publ) invites investors to a presentation of the first quarter 2024 at 15:00 CEST on May 15. The interim report for the first quarter will be published at 8:00 a.m. CEST on the same day.

Implantica AG (publ.), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra. Beatriz Guil of Universitario de Canarias in the Canary Islands and Dr. Carlos Milliani of Universitario de Fuenlabrada in the Madrid Region are offering their patients the RefluxStop™ procedure.

The depository receipt holders of Implantica AG, reg. no. FL-0002.629.889-3, are hereby invited to attend the annual general meeting to be held on Wednesday, May 22, 2024, at 14:30 at Hotel Kommod, Industriering 14, 9491 Ruggell, Liechtenstein.